Pubblicazioni

1. Paganelli G, Sansovini M, Nicolini S, Grassi I, Ibrahim T, Amadori E, Di Iorio V, Monti M, Scarpi E, Bongiovanni A, Altini M, Urso L, Cittanti C, Matteucci F, Severi S. 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):152-160. doi: 10.1007/s00259-020-04873-0. Epub 2020 May 29. PMID: 32472437.
2. Panareo S, Urso L, Santi I, Rigolin GM, Cuneo A, Cittanti C, Bartolomei M. Right Atrium Mass Assessed with 18F-FDG PET/CT Scan Turns Out to Be an Uncommon Relapse of Testicular Diffuse Large B-cell Lymphoma: A Case Report. Diagnostics (Basel). 2020 Nov 23;10(11):987. doi: 10.3390/diagnostics10110987. PMID: 33238362; PMCID: PMC7700395.
3. Quartuccio N, Panareo S, Urso L, Sturiale L, Siracusa M, Arnone A, Alongi P, Baldari S, Bartolomei M, Arnone G. Initial results of the use of a novel semiquantitative parameter in three-phase bone scan to predict 99mTc-HMPAO-labeled leukocyte scintigraphy in patients with unilateral total knee replacement. Nucl Med Commun. 2021 Feb 1;42(2):198-204. doi: 10.1097/MNM.0000000000001321. PMID: 33252511.
4. Uccelli L, Boschi A, Cittanti C, Martini P, Panareo S, Tonini E, Nieri A, Urso L, Caracciolo M, Lodi L, Carnevale A, Giganti M and Bartolomei M. 90Y/177Lu-DOTATOC: From Preclinical Studies to Application in Humans. Pharmaceutics. 2021 Sep 13;13(9):1463. doi: 10.3390/pharmaceutics13091463. PMID: 34575538; PMCID: PMC8469896.
5. Cistaro, A., Quartuccio, N., Garganese, M. C., Villani, M. F., Altini, C., Pizzoferro, M., Piccardo, A., Cabria, M., Massollo, M., Maghnie, M., Campennì, A., Siracusa, M., Baldari, S., Panareo, S., Urso, L., Bartolomei, M., De Palma, D., Grossi, A., Mazzoletti, A., Dondi, F., … Albano, D. (2022). Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study. European journal of nuclear medicine and molecular imaging, 49(4), 1374–1385. https://doi.org/10.1007/s00259-021-05586-8
6. Urso L, Quartuccio N, Caracciolo M, Evangelista L, Schirone A, Frassoldati A, Arnone G, Panareo S, Bartolomei M. Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer. Nucl Med Commun. 2022 Feb 1;43(2):212-219. doi: 10.1097/MNM.0000000000001500. PMID: 35022378.
7. Panareo S, Urso L, Nieri A, Caracciolo M, Valpiani G, Torricelli P, Frassoldati A, Cittanti C, Rollo M, Bartolomei M. Clinical-Diagnostic Relevance of Breast "Incidentaloma" Detected During 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography: Correlation with Radiological Imaging and Histopathology. Indian J Nucl Med. 2021 Oct-Dec;36(4):385-390. doi: 10.4103/ijnm.ijnm_52_21. Epub 2021 Dec 15. PMID: 35125756; PMCID: PMC8771069.
8. Urso L, Ortolan N, Panareo S, Stefanelli A, Cuneo A, Bartolomei M. Uncommon solitary nasal extramedullary plasmacytoma detected by 18F-FDG PET/CT. Hell J Nucl Med. 2021 Sep-Dec;24(3):265-266. doi: 10.1967/s002449912409. Epub 2021 Dec 17. PMID: 34901966.
9. Urso, L.*, Castello, A.*, Rocca, G. C., Lancia, F., Panareo, S., Cittanti, C., Uccelli, L., Florimonte, L., Castellani, M., Ippolito, C., Frassoldati, A., & Bartolomei, M. (2022). Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives. Journal of cancer research and clinical oncology, 148(6), 1299–1311. PMID: 35217902.
10. Castello A, Castellani M, Florimonte L, Urso L, Mansi L, Lopci E. The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria. J Clin Med. 2022;11(6):1740. Published 2022 Mar 21. doi:10.3390/jcm11061740
11. Urso L, Lancia F, Ortolan N, Frapoli M, Rauso M, Artioli P, Cittanti C, Uccelli L, Frassoldati A, Evangelista L, Bartolomei M. 18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready? Clin Transl Imaging. 2022;10(6):687-695. doi: 10.1007/s40336-022-00515-7. Epub 2022 Jul 28. PMID: 35919380; PMCID: PMC9333077.
12. Uccelli L, Martini P, Urso L, Ghirardi T, Marvelli L, Cittanti C, Carnevale A, Giganti M, Bartolomei M, Boschi A. Rhenium Radioisotopes for Medicine, a Focus on Production and Applications. Molecules. 2022 Aug 18;27(16):5283. doi: 10.3390/molecules27165283. PMID: 36014521; PMCID: PMC9412410.
13. Urso L, Nieri, A., Rambaldi, I., Castello, A., Uccelli, L., Cittanti, C., Panareo, S., Gagliardi, I., Ambrosio, M. R., Zatelli, M. C., & Bartolomei, M. (2022). Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review. Endocrine, 78(2), 255–261. https://doi.org/10.1007/s12020-022-03170-0
14. Urso, L., Panareo, S., Castello, A., Ambrosio, M. R., Zatelli, M. C., Caracciolo, M., Tonini, E., Valpiani, G., Boschi, A., Uccelli, L., Cittanti, C., & Bartolomei, M. (2022). Glucose Metabolism Modification Induced by Radioligand Therapy with [¹⁷⁷Lu]Lu/[⁹⁰Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial. Pharmaceutics, 14(10), 2009. https://doi.org/10.3390/pharmaceutics14102009.
15. Urso, L., Rocca, G. C., Borgia, F., Lancia, F., Malorgio, A., Gagliano, M., Zanetto, M., Uccelli, L., Cittanti, C., Ippolito, C., Evangelista, L., & Bartolomei, M. (2022). The Role of [18F]F-Choline PET/CT in the Initial Management and Outcome Prediction of Prostate Cancer: A Real-World Experience from a Multidisciplinary Approach. Biomedicines, 10(10), 2463. https://doi.org/10.3390/biomedicines10102463
16. Caracciolo, M., Castello, A., Urso, L., Borgia, F., Ortolan, N., Uccelli, L., Cittanti, C., Castellani, M., Bartolomei, M., Lazzeri, M., & Lopci, E. (2022). The Role of [⁶⁸Ga]PSMA PET/CT for Clinical Suspicion of Prostate Cancer in Patients with or without Previous Negative Biopsy: A Systematic Review. Cancers, 14(20), 5036. https://doi.org/10.3390/cancers14205036
17. Castello A, Caracciolo M, Urso L, Ortolan N, Nieri A, Panareo S, Bartolomei M. Incidental findings of acute myeloid leukemia in Sjögren's syndrome detected by nuclear medicine techniques. Indian J Nucl Med 2022;37:279-80. Doi:10.4103/ijnm.ijnm_126_21
18. Urso, L., Manco, L., Castello, A., Evangelista, L., Guidi, G., Castellani, M., Florimonte, L., Cittanti, C., Turra, A., & Panareo, S. (2022). PET-Derived Radiomics and Artificial Intelligence in Breast Cancer: A Systematic Review. International journal of molecular sciences, 23(21), 13409. https://doi.org/10.3390/ijms232113409
19. Urso, L., Nieri A, Borgia F, Malorgio A, Bartolomei M. Superscan-Like Pattern on 18F-Choline PET/CT in a Patient With Essential Thrombocythemia. Clin Nucl Med. 2023 Mar 1;48(3):e131-e132. doi: 10.1097/RLU.0000000000004474. PMID: 36723898.
20. Urso L, Evangelista L, Alongi P, Quartuccio N, Cittanti C, Rambaldi I, Ortolan N, Borgia F, Nieri A, Uccelli L, Schirone A, Panareo S, Arnone G, Bartolomei M. The Value of Semiquantitative Parameters Derived from ¹⁸F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer. Cancers. 2022; 14(23):5869. https://doi.org/10.3390/cancers14235869
21. Urso, L., Rocca GC, Uccelli L, Ippolito C, Bartolomei M. 18 F-Choline Versus 68 Ga-PSMA-11 PET/CT Imaging Comparison in Incidental Clear Cell Renal Cell Carcinoma. Clin Nucl Med. 2023 Apr 1;48(4):e178-e180. doi: 10.1097/RLU.0000000000004515. PMID: 36728284.
22. Evangelista, L., Bianchi, A., Annovazzi, A., Sciuto, R., Di Traglia, S., Bauckneht, M., Lanfranchi, F., Morbelli, S., Nappi, A. G., Ferrari, C., Rubini, G., Panareo, S., Urso, L., Bartolomei, M., D'Arienzo, D., Valente, T., Rossetti, V., Caroli, P., Matteucci, F., Aricò, D., … De Rimini, M. L. (2023). ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors. Cancers, 15(3), 878. https://doi.org/10.3390/cancers15030878
23. Urso, L., Castello, A., Treglia, G., Panareo, S., Nieri, A., Rambaldi, I., Caracciolo, M., Ortolan, N., Uccelli, L., Cittanti, C., Castellani, M., & Bartolomei, M. (2023). Relevance of Volumetric Parameters Applied to [68Ga]Ga-DOTATOC PET/CT in NET Patients Treated with PRRT. Diagnostics (Basel, Switzerland), 13(4), 606. https://doi.org/10.3390/diagnostics13040606
24. Nieri, A., Urso, L., Caracciolo, M., Ciccone, M., Uccelli, L., Cittanti, C., Cuneao, A. & Bartolomei, M. (2022). Misinterpretation of an inflammatory FDG uptake in a patient treated for Hodgkin lymphoma: a case report. Asia Oceania Journal of Nuclear Medicine & Biology, 11(2), 171-174. 10.22038/AOJNMB.2022.66011.1457.
25. Urso, L., Frantellizzi, V., De Vincentis, G.; Schillaci, O; Filippi, L; Evangelista, L. Clinical applications of long axial field-of-view PET/CT scanners in oncology. Clin Transl Imaging (2023). https://doi.org/10.1007/s40336-023-00547-7
26. Dondi, F.; Lazzarato, A.; Gorica, J.; Guglielmo, P.; Borgia, F.; Filice, R.; Vento, A.; Pacella, S.; Camedda, R.; Caracciolo, M.; De Feo, M.S.; Mammucci, P.; Frantellizzi, V.; Ortolan, N.; Fiasconaro, E.; Urso, L.; Evangelista, L.; Laudicella, R.; Santo, G., on behalf of Young Italian Association of Nuclear Medicine (AIMN) Working Group. PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score. Life 2023, 13, 611. https://doi.org/10.3390/life13030611
27. Filippi, L.*, Urso, L.*, Bianconi, F., Palumbo, B., Marzola, M. C., Evangelista, L., & Schillaci, O. (2023). Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach. Expert review of molecular diagnostics, 1–13. https://doi.org/10.1080/14737159.2023.2192351.
28. Urso, L.; Nieri, A.; Uccelli, L.; Castello, A.; Artioli, P.; Cittanti, C.; Marzola, M.C.; Florimonte, L.; Castellani, M.; Bissoli, S.; Porto, F.; Boschi, A.; Evangelista, L.; Bartolomei, M. Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE. Pharmaceutics 2023, 15, 1110. https://doi.org/10.3390/pharmaceutics15041110
29. Riondato, M., Rigamonti, D., Martini, P., Cittanti, C., Boschi, A., Urso, L., & Uccelli, L. (2023). Oldie but Goodie: Is Technetium-99m Still a Treasure Trove of Innovation for Medicine? A Patents Analysis (2000-2022). Journal of medicinal chemistry, 10.1021/acs.jmedchem.3c00148. Advance online publication. https://doi.org/10.1021/acs.jmedchem.3c00148
30. Urso, L.; Bonatto, E.; Nieri, A.; Castello, A.; Maffione, A.M.; Marzola, M.C.; Cittanti, C.; Bartolomei, M.; Panareo, S.; Mansi, L.; Lopci, E.; Florimonte, L.; Castellani, M. The Role of Molecular Imaging in Patients with Brain Metastases: A Literature Review. Cancers 2023, 15, 2184. https://doi.org/10.3390/cancers15072184
31. Urso, L., Rocca, G.C., Conti, G.M. et al. 68Ga-PSMA-11 PET/CT in Bilateral Clear Cell Renal Cell Carcinoma: an Intra-patient Comparison Between High and Low Grade Tumors. Nucl Med Mol Imaging (2023). https://doi.org/10.1007/s13139-023-00805-6
32. Bianchi, A., De Rimini, M. L., Sciuto, R., Annovazzi, A., Di Traglia, S., Bauckneht, M., Lanfranchi, F., Morbelli, S., Nappi, A. G., Ferrari, C., Rubini, G., Panareo, S., Urso, L., Bartolomei, M., D'Arienzo, D., Valente, T., Rossetti, V., Caroli, P., Matteucci, F., Aricò, D., … Evangelista, L. (2023). Can Baseline [18F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study. Cancer biotherapy & radiopharmaceuticals, 38(4), 256–267. https://doi.org/10.1089/cbr.2022.0092
33. Quartuccio, N.; Alongi, P.; Urso, L.; Ortolan, N.; Borgia, F.; Bartolomei, M.; Arnone, G.; Evangelista, L. ¹⁸F-FDG PET-Derived Volume-Based Parameters to Predict Disease-Free Survival in Patients with Grade III Breast Cancer of Different Molecular Subtypes Candidates to Neoadjuvant Chemotherapy. Cancers 2023, 15, 2715. https://doi.org/10.3390/cancers15102715
34. Filippi, L., Urso, L., Schillaci, O., & Evangelista, L. (2023). Hepato-Biliary Imaging in an Acute Setting: Is There a Role for Nuclear Medicine?. Seminars in nuclear medicine, S0001-2998(23)00038-7. Advance online publication. https://doi.org/10.1053/j.semnuclmed.2023.05.002.
35. Evangelista L, Urso L, Caracciolo M, et al. FDG PET/CT Volume-Based Quantitative Data and Survival Analysis in Breast Cancer Patients: A Systematic Review of the Literature [published online ahead of print, 2022 Mar 29]. Curr Med Imaging. 2022;10.2174/1573405618666220329094423. doi:10.2174/1573405618666220329094423
36. Bianchini C, Caracciolo M, Urso L, Ciorba A, Bonsembiante A, Migliorelli A, Corazzi V, Carandina I, Ortolan N, Cittanti C, Uccelli L, Pelucchi S, Panareo S, Bartolomei M. Role of 18F-FDG PET/CT in evaluating lymph node status in patients with head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital. 2023 May 23. doi: 10.14639/0392-100X-N2370. Epub ahead of print. PMID: 37224172.
37. Evangelista L, Fiz F, Laudicella R, Bianconi F, Castello A, Guglielmo P, Liberini V, Manco L, Frantellizzi V, Giordano A, Urso L, Panareo S, Palumbo B, Filippi L. PET Radiomics and Response to Immunotherapy in Lung Cancer: A Systematic Review of the Literature. Cancers (Basel). 2023 Jun 20;15(12):3258. doi: 10.3390/cancers15123258. PMID: 37370869; PMCID: PMC10296704.
38. Filippi L, Urso L, Schillaci O, Evangelista L. [18F]-FDHT PET for the Imaging of Androgen Receptor in Prostate and Breast Cancer: A Systematic Review. Diagnostics (Basel). 2023 Aug 7;13(15):2613. doi: 10.3390/diagnostics13152613. PMID: 37568977; PMCID: PMC10417772.
39. Caracciolo M, Castello A, Urso L, Borgia F, Marzola MC, Uccelli L, Cittanti C, Bartolomei M, Castellani M, Lopci E. Comparison of MRI vs. [18F]FDG PET/CT for Treatment Response Evaluation of Primary Breast Cancer after Neoadjuvant Chemotherapy: Literature Review and Future Perspectives. J Clin Med. 2023 Aug 17;12(16):5355. doi: 10.3390/jcm12165355. PMID: 37629397; PMCID: PMC10455346.
40. Nieri A, Manco L, Bauckneht M, Urso L*, Caracciolo M, Donegani MI, Borgia F, Vega K, Colella A, Ippolito C, Cittanti C, Morbelli S, Sambuceti G, Turra A, Panareo S, Bartolomei M. [18F]FDG PET-TC radiomics and machine learning in the evaluation of prostate incidental uptake. Expert Rev Med Devices. 2023 Nov 9:1-9. doi: 10.1080/17434440.2023.2280685. Epub ahead of print. PMID: 37942630.
41. Urso L, Filippi L, Castello A, Marzola MC, Bartolomei M, Cittanti C, Florimonte L, Castellani M, Zucali P, Bruni A, Sabbatini R, Dominici M, Panareo S, Evangelista L. PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality? J Clin Med. 2023 Nov 16;12(22):7130. doi: 10.3390/jcm12227130. PMID: 38002742; PMCID: PMC10672135.
42. Filippi L, Urso L, Frantellizzi V, Marzo K, Marzola MC, Schillaci O, Evangelista L. Molecular imaging of PARP in cancer: state-of-the-art. Expert Rev Mol Diagn. 2023 Nov 27. doi: 10.1080/14737159.2023.2287503. Epub ahead of print. PMID: 38009232.
43. Urso L, Bauckneht M, Albano D, Chondrogiannis S, Grassetto G, Lanfranchi F, Dondi F, Fornarini G, Lazzeri M, Evangelista L. The evolution of PET imaging in renal, bladder, upper urinary tract urothelial, testicular and penile carcinoma - Today's impact, tomorrow's potential. Expert Rev Med Devices. 2023 Dec 10. doi: 10.1080/17434440.2023.2293919. Epub ahead of print. PMID: 38072680.

Pubblicazioni Scientifiche non Indicizzate SCOPUS

44. Urso, L., Panareo, S. Il linfonodo sentinella nel carcinoma differenziato della tiroide. L'Endocrinologo 23, 345–349 (2022). https://doi.org/10.1007/s40619-022-01128-y

45. Urso, L., Bartolomei, M., Panareo, S. La paratiroidectomia radioguidata: quando e come. L'Endocrinologo volume 23, pages465–468 (2022). DOI: 10.1007/s40619-022-01149-7